A protein engineering platform spawns a new IL-2 player out of Basel, with human trials looming next summer
Versant Ventures is debuting another biotech upstart this morning that its partners believe has big potential for developing pipelines in products created by its own unique platform tech. And they have their sights set first on one of the hottest targets in immuno-oncology.
The company is Bright Peak Therapeutics, launched out of Versant’s Ridgeline Therapeutics Discovery Engine in Basel, which is growing clinical development roots in San Diego. And they have $35 million of Versant A round cash to fund their drive to the clinic.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters